Teràpies experimentals en neoplàsies limfoides

Publicacions destacades

Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia

Gimenez, Neus; Schulz, Ralph; Higashi, Morihiro; Aymerich, Marta; Villamor, Neus;

(...)

Lopez-Guerra, Monica; Campo, Elias; Rosich, Laia; Seiffert, Martina; Colomer, Dolors.

Referència:
Leukemia 2020.
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia

Lee-Verges, Eriong; Hanna, Bola S; Yazdanparast, Haniyeh; Rodriguez, Vanina; Leonor Rodriguez, Marta;

(...)

Perez-Galan, Patricia; Lopez-Guerra, Monica; Campo, Elias; Seiffert, Martina; Colomer, Dolors.

Referència:
International Journal Of Cancer 2019.
Control of chronic lymphocytic leukemia development by clonally-expanded CD8+T-cells that undergo functional exhaustion in secondary lymphoid tissues

Hanna B; Roessner P; Yazdanparast H; Colomer D; Campo E;

(...)

Stilgenbauer S; Schmidt M; Gabriel R; Lichter P; Seiffert M.

Referència:
Leukemia 2019.
Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

Gimenez, Neus; Martinez-Trillos, Alejandra; Montraveta, Arnau; Lopez-Guerra, Monica; Rosich, Laia;

(...)

Lopez-Otin, Carlos; Lopez-Guillermo, Armando; Campo, Elias; Colomer, Dolors; Villamor, Neus.

Referència:
Haematologica 2019.
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

Vidal-Crespo, Anna; Rodriguez, Vanina; Matas-Cespedes, Alba; Lee, Eriong; Rivas-Delgado, Alfredo;

(...)

Lopez-Guillermo, Armando; Lopez-Guerra, Monica; Roue, GaeL; Colomer, Dolors; Perez-Galan, Patricia.

Referència:
Haematologica 2017.
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia

Matas-Cespedes, Alba; Vidal-Crespo, Anna; Rodriguez, Vanina; Villamor, Neus; Delgado, Julio;

(...)

Wiestner, Adrian; Parren, Paul W H I; Doshi, Parul; van Bueren, Jeroen Lammerts; Perez-Galan, Patricia.

Referència:
Clinical Cancer Research 2017.
New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.

Tripathi R; Lee-Verges E; Higashi M; Gimenez N; Rosich L;

Lopez-Guerra M; Colomer D .

Referència:
Expert Opinion On Drug Discovery 2017.
The gamma-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells

Lopez-Guerra, M; Xargay-Torrent, S; Rosich, L; Montraveta, A; Roldan, J;

(...)

Lopez-Otin, C; Perez-Galan, P; Roue, G; Campo, E; Colomer, D.

Referència:
Leukemia 2015.
Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome

Martinez-Trillos, Alejandra; Pinyol, Magda; Navarro, Alba; Aymerich, Marta; Jares, Pedro;

(...)

Rozman, Ciril; Lopez-Otin, Carlos; Campo, Elias; Lopez-Guillermo, Armando; Villamor, Neus.

Referència:
Blood 2014.
NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome

Villamor, N; Conde, L; Martinez-Trillos, A; Cazorla, M; Navarro, A;

(...)

Lopez-Otin, C; Jares, P; Pereira, A; Campo, E; Lopez-Guillermo, A.

Referència:
Leukemia 2013.